Linagliptin Add-on to Insulin Background Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 11, 2019

Study Completion Date

January 18, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

placebo

DRUG

linagliptin

DRUG

background therapy

insulin with or without metformin

Trial Locations (25)

30052

Tianjin Medical University General Hospital, Tianjin

100029

China-Japan Friendship Hospital, Beijing

100730

Beijing Tongren Hospital, Beijing

100854

The General Hospital of Chinese People's Armed Police Forces, Beijing

110072

Shengjing Hospital of China Medical University, Shengyang

130021

First Hospital of Jilin University, Changchun

136000

Siping Central People's Hospital, Siping

200062

Centre Hospital of Putuo District, Shanghai, Shanghai

200072

Shanghai Tenth People's Hospital, Shanghai

200090

Yangpu Hospital, Tongji University, Shanghai

210006

Nanjing First Hospital, Nanjing

212013

Affiliated Hospital of Jiangsu University, Zhenjiang

215006

The First Affiliated Hospital of Soochow University, Suzhou

250000

General Hospital of Jinan Military Area, Jinan

266005

The affiliated hospital of medicalcollege qingdao university, Qingdao

300000

Nankai University Affiliated Hospital, Tianjin

The 2nd Hospital of Tianjin Medical University, Tianjin

310015

The Affiliated Hospital of Hangzhou Normal University, Hangzhou

350025

No.900 Hospital of PLA Joint Logistics Support Force, Fuzhou

361003

First Affiliated Hospital of Xiamen University, Xiamen

414000

the first people hospital of Yue Yang, Yueyang

430060

Renmin Hospital of Wuhan University, Wuhan

510150

Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

515041

Second Hospital Affiliated to Shantou Medical University, Shantou

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT02897349 - Linagliptin Add-on to Insulin Background Therapy | Biotech Hunter | Biotech Hunter